ArticlePLoS medicine2026
Medication adherence and its associated factors among oral pre-exposure prophylaxis (PrEP) users in China: The Real-world E-consumer Cohort of PrEP study.
Article in PLoS medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedication adherence is the key to success of HIV pre-exposure prophylaxis (PrEP). In China, the majority of real-world users purchase PrEP through e-commerce platforms, yet their adherence remains unaddressed. This cohort study aimed to evaluate PrEP adherence and its associated factors among e-consumers in China. METHODS AND
findingsEligible participants who had purchased PrEP online in the past 3 months were enrolled in the Real-world E-consumer Cohort of PrEP (RECOPE) in December 2023. Anonymous self-administered e-questionnaires were used at baseline and 1-, 3-, and 6-month follow-ups to collect data on PrEP adherence and potentially associated factors. Optimal adherence was defined as full compliance with the '2-1-1' dosing protocol for event-driven (ED) users and no missed pills in the past month for daily users. Generalized linear mixed-effects models and logistic regression were fitted to identify prognostic factors of PrEP adherence. Of 877 individuals invited, 680 were eligible and 657 completed the baseline survey (response rate 96.6%). The follow-up response rate at the 1-, 3-, and 6-month timepoints was 90.1% (592/657), 82.6% (543/657), and 80.1% (526/657), respectively. Among the 621 participants who had initiated PrEP at baseline, 529 (85.2%) used the ED regimen, and 92 (14.8%) used the daily regimen. Among ED users, the prevalence of optimal adherence at the four timepoints was 41.3% (154/373), 43.1% (146/339), 45.3% (139/307), and 52.6% (160/304), respectively. Among daily users, the prevalence of optimal adherence was 83.7% (77/92), 81.4% (83/102), 87.8% (86/98), 84.3% (75/89) at each survey wave, respectively. Within this group, the mean adherence rates in the past month ranged from 97.1% to 98.7% across waves. Among ED users, older age, receptive or versatile sexual role, and higher self-efficacy were positively associated with optimal adherence, while multiple same-sex partners, chemsex, and PrEP-related stigma were negatively associated factors. Selection bias, recall bias, social desirability bias, confounding bias, and limited representativeness were the main limitations of the study.
conclusionThe study found PrEP adherence was low among ED PrEP users who account for the majority of real-world e-consumers in China. Targeted interventions are suggested to prioritize enhancing users' understanding of medication instructions, promoting self-efficacy of maintaining adherence, and alleviating PrEP-related stigma. Additional attention should be given to ED users who have chemsex, insertive anal sex, multiple sexual partners, or a younger age.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.